

08/08/2003

=> d his ful

(FILE 'HOME' ENTERED AT 16:37:38 ON 08 AUG 2003)

FILE 'REGISTRY' ENTERED AT 16:48:02 ON 08 AUG 2003

L14 STR
 L15 6 SEA SSS SAM L14
 L16 SCREEN 2021
 L17 116 SEA SSS FUL L14 NOT L16
 L18 113 SEA ABB=ON L17 AND NR<6
 L19 113 SEA ABB=ON L18 AND NRS<6

FILE 'HCAPLUS' ENTERED AT 17:01:48 ON 08 AUG 2003

2 SEA ABB=ON L19

L20

FILE 'REGISTRY' ENTERED AT 17:10:06 ON 08 AUG 2003

L21 STR L14
 L22 1 SEA SSS SAM L21
 L23 27 SEA SSS FUL L21
 L24 STR L21
 L25 0 SEA SSS SAM L24
 L26 2 SEA SSS FUL L24
 L27 STR L21
 L28 0 SEA SSS SAM L27
 L29 0 SEA SSS FUL L27
 L30 STR L27
 L31 0 SEA SSS SAM L30
 L32 0 SEA SSS FUL L30
 L33 STR L21
 L34 0 SEA SSS SAM L33
 L35 0 SEA SSS FUL L33
 L36 STR L33
 L37 0 SEA SSS SAM L36
 L38 0 SEA SSS FUL L36
 L39 STR L36
 L40 0 SEA SSS SAM L39
 L41 0 SEA SSS FUL L39
 L42 2 SEA ABB=ON (393580-25-1 OR 393580-84-2)/RN

2 cit's for generic structure L14 - see d gne stat, attached. These 2 cit's are included herewith.

Pls. see attached d gne stat's keyed to the structures you furnished.

Str. 1 was located among these 27, & RN searched - see below.

Str. 26 - was one of these 2

> str for 3b - no hits

) str for 3a - no hits

Str. 1

Str. 26

FILE 'HCAPLUS' ENTERED AT 17:45:47 ON 08 AUG 2003

1 SEA ABB=ON L42

L43

FILE 'REGISTRY' ENTERED AT 18:17:04 ON 08 AUG 2003

1 SEA ABB=ON 393580-82-0/RN

L44

FILE 'HCAPLUS' ENTERED AT 18:17:22 ON 08 AUG 2003

1 SEA ABB=ON L44

L45

L46

1 SEA ABB=ON L43 OR L44

The same cit. for str 2a

This cit. was included here

Str. 2a - located by manual examination of L20 cit's.

Cocaine structure


Mondesi 09/909,012

08/08/2003

=> d que stat 120

L14

STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 38

STEREO ATTRIBUTES: NONE

L16

SCR 2021

L17

116 SEA FILE=REGISTRY SSS FUL L14 NOT L16

L18

113 SEA FILE=REGISTRY ABB=ON L17 AND NR<6

L19

113 SEA FILE=REGISTRY ABB=ON L18 AND NRS<6

→ L20


2 SEA FILE=HCAPLUS ABB=ON L19 *2 cit*

Structure for compd. ①

Mondesi 09/909,012

08/08/2003

=> d que stat l21
L21 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 44

STEREO ATTRIBUTES: NONE

Structure for 26


Mondesi 09/909,012

08/08/2003

=> d que stat 124

L24

STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 50


STEREO ATTRIBUTES: NONE

Structure for 3a

Mondesi 09/909,012

08/08/2003

=> d que stat 139
L39 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 53


STEREO ATTRIBUTES: NONE

Structure for 3b

Mondesi 09/909,012

08/08/2003

=> d que stat 133
L33 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 53

STEREO ATTRIBUTES: NONE

=> d ibib abs hitstr 120 1-2

L20 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2002:466030 HCAPLUS
 DOCUMENT NUMBER: 137:47444

TITLE: Preparation of diaryl peptides as NS3-serine protease
 inhibitors of hepatitis C virus
 INVENTOR(S): Zhu, Zhaoning; Sun, Zhong-Yue; Venkatraman, Srikanth;
 Njoroge, F. George; Arasappan, Ashok; Malcolm, Bruce
 A.; Girijavallabhan, Viyyoor M.; Lovey, Raymond G.;
 Chen, Kevin X.

PATENT ASSIGNEE(S): Schering Corporation, USA
 SOURCE: PCT Int. Appl., 149 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002048172	A2	20020620		
WO 2002048172	A3	20030619	WO 2001-US47383	20011210

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU,
 ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD,
 MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK,
 SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG



AU 2002036591 A5 20020624
 US 2002147139 A1 20021010

PRIORITY APPLN. INFO.:

AU 2002-36591 20011210
 US 2001-13071 20011210
 US 2000-254869P P 20001212
 WO 2001-US47383 W 20011210

OTHER SOURCE(S):
 GI

MARPAT 137:47444



AB Title compds. I [X, Y = (cyclo)alkyl, heteroalkyl, (aryl)heteroaryl, alkyl(hetero)aryl, substituted ether, sulfide, sulfone, amide, sulfonamide, urea, carbamate, hydrazide, carbonyl, etc.; W = null, CO, CS, or SO₂; Q = null, CH, N, P, alkylene, O, imino, S, or SO₂; A = O, CH₂, alkylene, imino, S, SO₂, or a bond; E = CH or substituted methylidyne, N, or a double bond toward A, L, or G; G = null or alkylene; J = null or alkylene, SO₂, imino, or O; L = null or CH or substituted methylidyne, O, S, or imino; M = null or O, imino, S, SO₂, or alkylene; P1a, P1b, P1', P3 = H, alkyl, alkenyl, cycloalkyl, heterocyclyl, (cycloalkyl)alkyl, or (heterocyclyl)alkyl; P1aP1bC may form a ring; Z = O or imino; Ar1, Ar2 = (un)substituted Ph, 2-, 3-, or 4-pyridyl or their N-oxides, 2- or 3-furanyl, etc.; P4 = H, alkyl, arylalkyl, or aryl; R2 = H, cyano, CF₃, (cyclo)alkyl, aryl, carboxy, etc. (with provisos)] were prepd. as hepatitis C virus (HCV) protease inhibitors. Thus, compd. II was prepd. by a multi-step procedure and showed K_i = 100-999 nM for inhibition of serine protease.

IT **393580-15-9P 437768-31-5P**


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of diaryl peptides as NS3-serine protease inhibitors of hepatitis C virus)

RN 393580-15-9 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2,2-diphenyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 437768-31-5 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2,2-diphenyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:90007 HCAPLUS

DOCUMENT NUMBER: 136:151439

TITLE: Preparation of novel peptides as NS3-serine protease inhibitors of hepatitis C virus

INVENTOR(S): Saksena, Anil K.; Girijavallabhan, Viyyoor Moopil; Bogen, Stephane L.; Lovey, Raymond G.; Jao, Edwin E.; Bennett, Frank; McCormick, Jinping L.; Wang, Haiyan; Pike, Russell E.; Liu, Yi-Tsung; Chan, Tin-Yau; Zhu, Zhaoning; Arasappan, Ashok; Chen, Kevin X.; Venkatraman, Srikanth; Parekh, Tejal N.; Pinto, Patrick A.; Santhanam, Bama; Njoroge, F. George; Ganguly, Ashit K.; Vaccaro, Henry A.; Kemp, Scott; Jeffrey, Levy, Odile Esther; Lim-Wilby, Marguerita; Tamura, Susan Y.

PATENT ASSIGNEE(S): Schering Corporation, USA; Corvas International, Inc.

SOURCE: PCT Int. Appl., 188 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008187	A1	20020131	WO 2001-US22813	20010719
WO 2002008187	C2	20030103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002160962	A1	20021031	US 2001-909012	20010719
EP 1303487	A1	20030423	EP 2001-959041	20010719
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012666	A	20030610	BR 2001-12666	20010719
NO 2003000271	A	20030318	NO 2003-271	20030120
PRIORITY APPLN. INFO.:				
US 2000-220107P P 20000721				
WO 2001-US22813 W 20010719				
OTHER SOURCE(S): MARPAT 136:151439				
GI				



AB Novel peptides I [G, J, Y = independently H, alkyl, alkyl-aryl, heteroalkyl, heteroaryl, aryl-heteroaryl, alkyl-heteroaryl, cycloalkyl, alkoxy, alkyl-aryloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, cycloalkyloxy, alkylamino, arylamino, alkyl-arylamino, arylamino, heteroarylamino, cycloalkylamino, and heterocycloalkylamino; Z = O, N, CH; W = null, CO, CS, SO₂; R₁ = COR₅, B(OR)₂; R₅ = H, OH, OR₈, NR₉R₁₀, CF₃, C₂F₅, C₃F₇, R₆, COR₇; R₇ = H, OH, OR₈, CHR₉R₁₀, NR₉R₁₀; R₆, R₈-10 = independently H, alkyl, aryl, heteroalkyl, cycloalkyl, arylalkyl, peptide deriv., etc.; R, R₂-4 = independently H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, alkoxy, aryloxy, alkylthio, arylthio, amino, amido,

ester, carboxylic acid, carbamate, etc.] and their pharmaceutically salts which have hepatitis C virus (HCV) protease inhibitory activity were prepd. via soln. or solid-phase peptide coupling methods. Thus, peptide II was prepd. using solid-phase methods and showed a K_i value in the range of 0-100 nM for HCV protease inhibitory activity. This invention also discloses pharmaceutical compns. comprising such compds. as well as methods of using them to treat disorders assocd. with the HCV protease.

IT 393580-04-6P 393580-05-7P 393580-06-8P
 393580-07-9P 393580-08-0P 393580-09-1P
 393580-10-4P 393580-11-5P 393580-12-6P
 393580-13-7P 393580-15-9P 393580-16-0P
 393580-17-1P 393580-18-2P 393580-19-3P
 393580-20-6P 393580-21-7P 393580-22-8P
 393580-23-9P 393580-25-1P 393580-26-2P
 393580-27-3P 393580-28-4P 393580-30-8P
 393580-31-9P 393580-40-0P 393580-41-1P
 393580-52-4P 393580-54-6P 393580-55-7P
 393580-56-8P 393580-59-1P 393580-60-4P
 393580-61-5P 393580-79-5P 393580-80-8P
 393580-81-9P 393580-82-0P 393580-83-1P
 393580-84-2P 393580-85-3P 393580-86-4P
 393580-87-5P 393580-89-7P 393580-92-2P
 393580-93-3P 393580-97-7P 393581-00-5P
 393581-01-6P 393581-02-7P 393581-03-8P
 393581-04-9P 393581-05-0P 393581-06-1P
 393581-07-2P 393581-11-8P 393581-12-9P
 393581-13-0P 393581-14-1P 393581-15-2P
 393581-16-3P 393581-17-4P 393581-18-5P
 393581-19-6P 393581-20-9P 393581-77-6P
 393582-01-9P 393582-02-0P 393582-03-1P
 393582-04-2P 393582-05-3P 393582-06-4P
 393582-07-5P 393582-08-6P 393582-12-2P
 393582-13-3P 393582-14-4P 393582-16-6P
 393582-17-7P 393582-18-8P 393582-26-8P
 393582-28-0P 393582-30-4P 393582-31-5P
 393582-32-6P 393582-33-7P 393582-34-8P
 393582-35-9P 393582-36-0P 393582-37-1P
 393582-38-2P 393582-39-3P 393582-40-6P
 393582-45-1P 393582-51-9P 393582-52-0P
 393582-53-1P 393582-54-2P 393582-55-3P
 393582-57-5P 393582-58-6P 393817-40-8P
 394203-62-4P 394203-63-5P 394203-64-6P
 394203-75-9P 394203-76-0P 394203-77-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of novel peptides as NS3-serine protease inhibitors of hepatitis C virus)

RN 393580-04-6 HCAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[[[4-pentylbicyclo[2.2.2]oct-1-yl]oxy]carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-05-7 HCAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-06-8 HCAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-
(.alpha.S)-.alpha.-aminobenzenebutanoyl-3-amino-2-oxohexanoylglycyl-2-
phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-07-9 HCAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-08-0 HCAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-4-bromo-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-09-1 HCAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-L-leucyl-3-amino-5,5,5-trifluoro-2-oxopentanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-10-4 HCAPLUS

CN Glycine, (2S)-N-(3-carboxy-1-oxo-3-phenylpropyl)-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, 5-(phenylmethyl) ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-11-5 HCAPLUS

CN Glycine, (2S)-N-(3-carboxy-1-oxo-3-phenylpropyl)-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393580-12-6 HCAPLUS

CN Glycine, (2S)-N-(4-carboxy-1-oxo-4-phenylbutyl)-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, 5-(phenylmethyl) ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

— Ph

RN 393580-13-7 HCAPLUS

CN Glycine, (2S)-N-(4-carboxy-1-oxo-4-phenylbutyl)-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-15-9 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2,2-diphenyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-16-0 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-4-fluoro-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-17-1 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-4-chloro-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-18-2 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-4-fluoro-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-19-3 HCAPLUS

CN Glycine, (2S)-N-(3-carboxy-1-oxo-5-heptenyl)-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, phenylmethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 393580-20-6 HCAPLUS

CN Glycine, (2S)-N-(3-carboxy-1-oxoheptyl)-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-21-7 HCAPLUS


CN Glycinamide, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-N-cyclohexyl-2-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393580-22-8 HCAPLUS
 CN Glycinamide, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-N-cyclohexyl-2-(4-ethoxyphenyl)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 393580-23-9 HCAPLUS
 CN Glycine, (2S)-N-acetyl-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-(4-phenoxyphenyl)glycyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393580-25-1 HCAPLUS
 CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-L-leucyl-3-amino-5-methyl-2-oxohexanoyl-2-13C-glycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-L-leucyl-3-amino-5-methyl-2-oxohexanoyl-2-¹³C-glycyl-2-phenyl-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Chemical structure of compound 13, showing a cyclohexyl group, a thioamide, a chiral center with a thioether and an amide, and a peptide-like chain ending in a thioether and a thioamide.


CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-4,5-didehydro-L-norvalyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI)
(CA INDEX NAME)

[illegible]

RN 393580-28-4 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-4,5-didehydro-L-norvalyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-30-8 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-[1,1'-biphenyl]-4-yl-L-alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-31-9 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-L-histidyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-40-0 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-(2-fluorophenyl)-, methyl ester, (2R)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 393580-41-1 HCAPLUS


CN Glycine, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-(2-fluorophenyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393580-52-4 HCAPLUS

CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 393580-54-6 HCAPLUS

CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-(1,3-dioxan-2-yl)alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 393580-55-7 HCAPLUS

CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-(1,3-dioxolan-2-yl)alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 393580-56-8 HCAPLUS


CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-(1,3-dioxolan-2-yl)alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 393580-59-1 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-60-4 HCAPLUS

CN Glycine, (2S)-N-(2-aminobenzoyl)-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-61-5 HCAPLUS


CN Glycine, (2S)-2-cyclohexyl-N-(2-hydroxybenzoyl)glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393580-79-5 HCAPLUS

CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-.alpha.-aminooxiranepropanoyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 393580-80-8 HCAPLUS

CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-4,5-dihydroxynorvalyl-3-amino-2-oxohexanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 393580-81-9 HCAPLUS

CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 393580-82-0 HCAPLUS

CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-4,5-didehydronorvalyl-3-amino-2-oxo-5-hexenoylglycyl-2-phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 393580-83-1 HCAPLUS

CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 393580-84-2 HCAPLUS


CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-4,5-didehydronorvalyl-3-amino-2-oxo-5-hexenoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 393580-85-3 HCAPLUS

CN Glycine, (2S)-N-[3-carboxy-5-(1,1-dimethylethyl)benzoyl]-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-86-4 HCAPLUS

CN Glycine, (2S)-N-[4-(carboxymethyl)-5,5-dimethyl-1-oxohexyl]-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-87-5 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-(4-fluorobenzoyl)glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-89-7 HCAPLUS


CN Glycine, (2S)-N-[2-(4-chlorophenyl)-2-methyl-1-oxopropyl]-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393580-92-2 HCAPLUS


CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl-, methyl ester (9CI) (CA INDEX NAME)



RN 393580-93-3 HCAPLUS


CN Glycinamide, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-

phenyl- (9CI) (CA INDEX NAME)




RN 393580-97-7 HCAPLUS

CN Glycine, .alpha.-hydroxybenzeneacetyl-2-cyclohexylglycyl-3-cyclopropylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 393581-00-5 HCAPLUS


CN Glycinamide, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-N-methoxy-N-methyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 393581-01-6 HCAPLUS


CN Glycinamide, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-N-

methoxy-2-phenyl- (9CI) (CA INDEX NAME)




RN 393581-02-7 HCAPLUS

CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropyl-N-methylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 393581-03-8 HCAPLUS


CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropyl-N-methylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 393581-04-9 HCAPLUS


CN Glycinamide, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropyl-N-methylalanyl-.beta.-amino-.alpha.-

oxocyclopropanebutanoylglycyl-N,N-dimethyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 393581-05-0 HCAPLUS

CN Glycinamide, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-N-(1,1-dimethylethyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 393581-06-1 HCAPLUS

CN Glycinamide, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropyl-N-methylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-N-methoxy-N-methyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 393581-07-2 HCAPLUS

CN Glycinamide, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-N,N-dimethyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 393581-11-8 HCAPLUS

CN Glycine, N-[(2-butynyloxy)carbonyl]-2-cyclohexylglycyl-3-cyclopropylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 393581-12-9 HCAPLUS

CN Glycine, 2-cyclohexyl-N-[(2-propynyloxy)carbonyl]glycyl-3-cyclopropylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 393581-13-0 HCAPLUS

CN Glycine, 2-cyclohexyl-N-[[(4,4-dimethyl-2-pentynyl)oxy]carbonyl]glycyl-3-cyclopropylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 393581-14-1 HCAPLUS

CN Glycine, 2-cyclohexyl-N-[(2-propynyloxy)carbonyl]glycyl-3-cyclopropylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 393581-15-2 HCAPLUS


CN Glycine, N-[(2-butynyloxy)carbonyl]-2-cyclohexylglycyl-3-cyclopropylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 393581-16-3 HCAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-N-methyl-L-leucyl-3-amino-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 393581-17-4 HCAPLUS


CN Glycinamide, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-N-methyl-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393581-18-5 HCAPLUS

CN Glycine, 2-cyclohexyl-N-(phenylacetyl)glycyl-3-cyclopropylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 393581-19-6 HCAPLUS

CN Glycine, 2-cyclohexyl-N-(phenylacetyl)glycyl-3-cyclopropylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 393581-20-9 HCAPLUS


CN Glycine, 2-cyclohexyl-N-(2-hydroxybenzoyl)glycyl-3-cyclopropylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 393581-77-6 HCAPLUS


CN Glycinamide, (2S)-N-(2-carboxy-3,6-difluorobenzoyl)-2-cyclohexylglycyl-L-leucyl-(3S)-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




CN Glycine, (2S)-N-[[4-(carboxymethyl)phenyl]acetyl]-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




CN Glycine, (2S)-N-[[3-(carboxymethyl)phenyl]acetyl]-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



CN Glycine, (2S)-N-(4-carboxybenzoyl)-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-04-2 HCAPLUS

CN Glycine, (2S)-N-(3-carboxybenzoyl)-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-05-3 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(cyclohexyloxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-06-4 HCAPLUS


CN Glycine, (2S)-2-cyclohexyl-N-[[4-(methoxycarbonyl)phenoxy]carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393582-07-5 HCAPLUS
 CN Glycine, (2S)-2-cyclohexyl-N-[(3-methoxy-2,2-dimethyl-3-oxopropoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393582-08-6 HCAPLUS
 CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393582-12-2 HCAPLUS
 CN Glycinamide, (2S)-N-(2-carboxy-3-methylbenzoyl)-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-13-3 HCAPLUS

CN Glycinamide, (2S)-N-(2-carboxy-3,6-difluorobenzoyl)-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-14-4 HCAPLUS

CN Glycinamide, (2S)-N-(2-carboxybenzoyl)-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-16-6 HCAPLUS

CN Glycinamide, (2S)-N-[(2-carboxy-1-cyclopenten-1-yl)carbonyl]-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-17-7 HCAPLUS

CN Glycinamide, (2S)-N-(2-carboxy-3-hydroxybenzoyl)-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-18-8 HCAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-(2,3,4,5,6-pentafluorobenzoyl)glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-26-8 HCAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[[[tetrahydro-3-furanyl)methoxy]carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-28-0 HCAPLUS

CN Glycine, (2S)-N-[(2-methylpropoxy)carbonyl]-2-phenylglycyl-L-leucyl-3-amino-5-methyl-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-30-4 HCAPLUS


CN Glycine, (2S)-N-[(2-methylpropoxy)carbonyl]-2-phenylglycyl-3-cyclopropyl-L-alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




CN Glycine, (2S)-N-[(2-methylpropoxy)carbonyl]-2-phenylglycyl-3-(1,3-dioxolan-2-yl)-L-alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



CN Glycine, (2S)-N-[(2-methylpropoxy)carbonyl]-2-phenylglycyl-3-(1,3-dioxan-2-yl)-L-alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-33-7 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropyl-L-alanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-34-8 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropyl-L-alanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-35-9 HCAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropyl-L-alanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-36-0 HCAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropyl-L-alanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-N-methoxy-N-methyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-37-1 HCAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropyl-L-alanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-38-2 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-4,5-didehydro-L-norvalyl-3-amino-2-oxo-5-hexenoylglycyl-2-phenyl-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-39-3 HCAPLUS


CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-4,5-didehydro-L-norvalyl-3-amino-2-oxo-5-hexenoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393582-40-6 HCAPLUS
 CN Glycine, (2S)-N-[3-(2-carboxyethyl)-4,4-dimethyl-1-oxopentyl]-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393582-45-1 HCAPLUS
 CN Glycine, (.alpha.S)-.alpha.-hydroxybenzeneacetyl-(2S)-2-cyclohexylglycyl-3-cyclopropyl-L-alanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-51-9 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[[[(4,4-dimethyl-2-pentynyl)oxy]carbonyl]glycyl-3-cyclopropyl-L-alanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoyl]glycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-52-0 HCAPLUS


CN Glycine, (2S)-2-cyclohexyl-N-[(2-propynyloxy)carbonyl]glycyl-3-cyclopropyl-L-alanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoyl]glycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393582-53-1 HCAPLUS
 CN Glycine, (2S)-N-[(2-butynyloxy)carbonyl]-2-cyclohexylglycyl-3-cyclopropyl-L-alanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393582-54-2 HCAPLUS
 CN Glycinamide, (2S)-N-(2-carboxybenzoyl)-2-cyclohexylglycyl-3-cyclopropyl-L-alanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393582-55-3 HCAPLUS
 CN Glycinamide, (2S)-N-(3-carboxybenzoyl)-2-cyclohexylglycyl-3-cyclopropyl-L-alanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-57-5 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclobutyl-L-alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-58-6 HCAPLUS


CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-O-phenyl-L-homoseryl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393817-40-8 HCAPLUS


CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-(1,3-dioxan-2-yl)alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 394203-62-4 HCAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[[[(3-methylbicyclo[2.2.1]hept-2-yl)methoxy]carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394203-63-5 HCAPLUS

CN Glycine, (2S)-N-[(3-carboxybicyclo[2.2.1]hept-2-yl)carbonyl]-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394203-64-6 HCAPLUS

CN Glycine, (2S)-N-[(3-carboxybicyclo[2.2.1]hept-5-en-2-yl)carbonyl]-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, phenylmethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394203-75-9 HCAPLUS

CN Glycine, (2S)-N-[(4-carboxycyclohexyl)carbonyl]-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394203-76-0 HCAPLUS

CN Glycine, (2S)-N-[(3-carboxycyclohexyl)carbonyl]-2-cyclohexylglycyl-L-

leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394203-77-1 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[[[4-(ethoxycarbonyl)cyclohexyl]oxy]carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 393581-45-8P 393581-59-4P 393581-64-1P
393581-69-6P 393581-77-6DP, resin-bound

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of novel peptides as NS3-serine protease inhibitors of hepatitis C virus)

RN 393581-45-8 HCAPLUS


CN Glycinamide, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-3-(2-naphthalenyl)-L-alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




CN Glycine, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-1-
[(phenylmethoxy)carbonyl]-L-histidyl-3-amino-2-oxohexanoylglycyl-2-phenyl-
, phenylmethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



CN Glycine, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-3-(5,6,7,8-tetrahydro-1-naphthalenyl)-L-alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, phenylmethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393581-69-6 HCAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-(phenylacetyl)glycyl-3-cyclopropyl-L-alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393581-77-6 HCAPLUS

CN Glycinamide, (2S)-N-(2-carboxy-3,6-difluorobenzoyl)-2-cyclohexylglycyl-L-leucyl-(3S)-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Mondesi 09/909,012

08/08/2003

REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Inventor Search



Mondesi 09/909,012

08/08/2003

=> d ibib abs hitstr 113 1-1

L13 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:90074 HCAPLUS
DOCUMENT NUMBER: 136:151440
TITLE: Preparation of novel peptides as NS3-serine protease
inhibitors of hepatitis C virus
INVENTOR(S): Saksena, Anil K.; Girijavallabhan,
Viyyoor Moopil; Lovey, Raymond G.; Jao,
Edwin E.; Bennett, Frank;
McCormick, Jinping; Wang, Haiyan; Pike,
Russell E.; Bogen, Stephane L.; Liu,
Yi-Tsung; Arasappan, Ashok; Parekh, Tejal; Pinto,
Patrick A.; Njoroge, F. George; Ganguly, Ashit K.;
Brunck, Terence K.; Kemp, Scott Jeffrey; Levy, Odile
Esther; Lim-Wilby, Marguerita
PATENT ASSIGNEE(S): Schering Corporation, USA; Corvas International, Inc.
SOURCE: PCT Int. Appl., 197 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008256	A2	20020131	WO 2001-US22826	20010719
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003036501	A1	20030220	US 2001-909062	20010719
EP 1301528	A2	20030416	EP 2001-959046	20010719
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRIORITY APPLN. INFO.:			US 2000-220109P P	20000721
			WO 2001-US22826 W	20010719
OTHER SOURCE(S):	MARPAT 136:151440			
GI				



AB Novel peptides I [Z = O, NH or substituted imino; X = (un)substituted alkylsulfonyl, heterocyclisulfonyl, heterocyclalalkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylcarbonyl, heterocyclalcarbonyl, heterocyclalalkylcarbonyl, arylcarbonyl, heteroarylcabonyl, alkoxy carbonyl, heterocyclaloxycarbonyl, aryloxy carbonyl, heteroaryloxy carbonyl, alkyaminocarbonyl, heterocyclalaminocarbonyl, arylaminocarbonyl, or heteroarylamino carbonyl; X1 = H, alkyl, arylmethyl; P1a, P1b, P2-P6 = H, (un)substituted alkyl, alkenyl, cycloalkyl, heterocyclal, cycloalkylalkyl, heterocyclalalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; P1a and P1b may optionally be joined to each other to form a spirocyclic or spiroheterocyclic ring contg. 0-6 oxygen, nitrogen, sulfur, or phosphorus atoms; P1' = H, (un)substituted alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, heterocyclal, heterocyclalalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl] having HCV protease inhibitory activity are disclosed. Thus, peptide II was prep'd. via peptide coupling in soln. and showed $K_i = 1-100$ nM for inhibition of HCV protease.

IT **149885-80-3**, NS3-NS4A protease

RL: BSU (Biological study, unclassified); BIOL (Biological study) (prepn. of novel peptides as NS3-serine protease inhibitors of hepatitis C virus)

RN 149885-80-3 HCAPLUS

CN Proteinase, polyprotein-processing, NS3 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **393519-93-2P 393520-05-3P**


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (prepn. of novel peptides as NS3-serine protease inhibitors of hepatitis C virus)

RN 393519-93-2 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) 7-(2-propenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

=CH₂

RN 393520-05-3 HCAPLUS
 CN Glycinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-N-2-propenyl-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

=CH₂

IT 393519-95-4P 393519-97-6P 393520-00-8P
 393520-02-0P 393520-03-1P 393520-07-5P
 393520-09-7P 393520-11-1P 393520-13-3P
 393520-15-5P 393520-17-7P 393520-19-9P
 393520-21-3P 393520-23-5P 393520-25-7P
 393520-27-9P 393520-29-1P 393520-31-5P
 393520-33-7P 393520-35-9P 393520-37-1P
 393520-49-5P 393520-51-9P 393520-53-1P
 393520-55-3P 393520-57-5P 393520-59-7P
 393520-61-1P 393520-63-3P 393520-65-5P
 393520-67-7P 393520-69-9P 393520-70-2P
 393520-72-4P 393520-74-6P 393520-76-8P

393520-79-1P 393520-81-5P 393520-83-7P
 393520-85-9P 393520-87-1P 393520-89-3P
 393520-91-7P 393520-93-9P 393520-95-1P
 393520-97-3P 393520-99-5P 393521-01-2P
 393521-03-4P 393521-05-6P 393521-07-8P
 393521-09-0P 393521-11-4P 393521-13-6P
 393521-15-8P 393521-17-0P 393521-19-2P
 393521-21-6P 393521-23-8P 393521-25-0P
 393521-27-2P 393521-29-4P 393521-31-8P
 393521-33-0P 393521-35-2P 393521-37-4P
 393521-39-6P 393521-41-0P 393521-43-2P
 393521-45-4P 393521-47-6P 393521-49-8P
 393521-51-2P 393521-53-4P 393521-55-6P
 393521-57-8P 393521-59-0P 393521-61-4P
 393521-65-8P 393521-67-0P 393521-69-2P
 393521-72-7P 393521-74-9P 393521-77-2P
 393521-79-4P 393521-81-8P 393521-82-9P
 393521-84-1P 393521-91-0P 393521-94-3P
 393521-98-7P 393522-01-5P 393522-04-8P
 393522-09-3P 393522-12-8P 393522-14-0P
 393522-17-3P 393522-20-8P 393522-22-0P
 393522-24-2P 393522-26-4P 393522-28-6P
 393522-30-0P 393522-32-2P 393522-34-4P
 393522-36-6P 393522-39-9P 393522-42-4P
 393522-44-6P 393522-46-8P 393522-48-0P
 393522-50-4P 393522-52-6P 393522-55-9P
 393522-59-3P 393522-62-8P 393522-65-1P
 393522-68-4P 393522-71-9P 393522-74-2P
 393522-76-4P 393522-79-7P 393522-81-1P
 393522-84-4P 393522-87-7P 393522-90-2P
 393522-93-5P 393522-96-8P 393522-99-1P
 393523-02-9P 393523-04-1P 393523-06-3P
 393523-09-6P 393523-12-1P 393523-15-4P
 393523-18-7P 393523-21-2P 393523-24-5P
 393523-27-8P 393523-29-0P 393523-31-4P
 393523-33-6P 393523-35-8P 393523-37-0P
 393523-39-2P 393523-41-6P 393523-43-8P
 393523-45-0P 393523-47-2P 393523-49-4P
 393523-51-8P 393523-53-0P 393523-55-2P
 393523-57-4P 393523-59-6P 393523-60-9P
 393523-62-1P 393523-64-3P 393523-65-4P
 393523-67-6P 393523-69-8P 393523-71-2P
 393523-73-4P 393523-75-6P 393523-77-8P
 393523-79-0P 393523-81-4P 393523-84-7P
 393523-86-9P 393523-89-2P 393523-92-7P
 393523-94-9P 393523-95-0P 393523-97-2P
 393523-99-4P 393524-00-0P 393524-02-2P
 393524-07-7P 393524-09-9P 393524-12-4P
 394203-31-7P 394203-32-8P 394203-33-9P
 394203-34-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(prepn. of novel peptides as NS3-serine protease inhibitors of
 hepatitis C virus)


RN 393519-95-4 HCAPLUS
 CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-
 prolyl-(3S)-3-amino-2-oxohexanoyl-, 7-(2-propenyl) ester (9CI) (CA INDEX
 NAME)

[illegible]

Absolute stereochemistry.




Absolute stereochemistry.



RN 393520-02-0 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-03-1 HCAPLUS

CN Glycinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-N-2-propenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-07-5 HCAPLUS

CN L-Proteinamide, N-acetyl-L-α-glutamyl-L-α-glutamyl-L-valyl-L-valyl-N-[1-(1S)-1-oxo(propylamino)acetyl]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-09-7 HCAPLUS

CN L-Proteinamide, N-acetyl-L-α-glutamyl-L-α-glutamyl-L-valyl-L-valyl-N-[1-(1S)-1-oxo(propylamino)acetyl]butyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-11-1 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[1-[(methyl-2-propenylamino)oxoacetyl]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393520-13-3 HCAPLUS


CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-4-
[(1,1-dimethylethoxy)carbonyl]-2-piperazinecarbonyl-3-amino-2-oxohexanoyl-
, 1,2-bis(1,1-dimethylethyl) 7-(2-propenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 393520-15-5 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-[oxo(2-propynylamino)acetyl]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-17-7 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-[oxo(2-propynylamino)acetyl]butyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393520-19-9 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) 7-(2-propynyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—C≡CH

RN 393520-21-3 HCAPLUS
 CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-, 7-(2-propynyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-23-5 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-[(3-carboxypropyl)amino]oxoacetyl]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-25-7 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-[(4-ethoxy-4-oxobutyl)amino]oxoacetyl]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-27-9 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-[[4-ethoxy-4-oxobutyl]amino]oxoacetyl]butyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-29-1 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-[[3-carboxypropyl]amino]oxoacetyl]butyl]-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-31-5 HCAPLUS

CN L-Methioninamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[1-(ethoxyoxoacetyl)butyl]-, bis(1,1-dimethylethyl) ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 393520-33-7 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4R)-4-[[(phenylmethoxy)carbonyl]amino]-L-prolyl-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) 7-(2-propenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

=CH₂



RN 393520-35-9 HCAPLUS
 CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-2-
 piperazinecarbonyl-3-amino-2-oxohexanoyl-, 7-(2-propenyl) ester (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 393520-37-1 HCAPLUS

CN L-Serinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-
 valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-N-methyl-O-(phenylmethyl)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-49-5 HCAPLUS
 CN L-Serinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-N-methyl-O-(phenylmethyl)-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—NHMe

—O—Ph

RN 393520-51-9 HCAPLUS
 CN .beta.-Alanine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) 7-ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-53-1 HCAPLUS

CN .beta.-Alanine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-55-3 HCAPLUS

CN .beta.-Alanine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-, 7-ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-57-5 HCAPLUS

CN L-Serine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-59-7 HCAPLUS

CN L-Serine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-, 7-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-61-1 HCAPLUS

CN L-Serine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-O-(1,1-dimethylethyl)-, 1,2-bis(1,1-dimethylethyl) 7-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-63-3 HCAPLUS

CN L-Serine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-O-(1,1-dimethylethyl)-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393520-65-5 HCAPLUS


CN 2-Azetidinecarboxamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]-, bis(1,1-dimethylethyl) ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 393520-67-7 HCAPLUS


CN 2-Azetidinecarboxamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B'




RN 393520-69-9 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-4-[(1,1-dimethylethoxy)carbonyl]-2-piperazinecarbonyl-3-amino-2-oxohexanoyl-

, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OBu-t

RN 393520-70-2 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-2-cyclohexylglycyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-72-4 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-2-cyclohexylglycyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]-, 2-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-74-6 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-
(4R)-4-[[(phenylmethoxy) carbonyl] amino]-L-prolyl-3-amino-2-oxohexanoyl-,
2-(1,1-dimethylethyl) 7-(2-propenyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-76-8 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-2-cyclohexylglycyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-79-1 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4R)-4-[[[(phenylmethoxy)carbonyl]amino]-L-prolyl-3-amino-2-oxohexanoyl]-7-(2-propenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393520-81-5 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) 7-(2-propenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

=CH₂

RN 393520-83-7 HCAPLUS
 CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-
 (4R)-4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-L-prolyl-3-amino-2-
 oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) 7-(2-propenyl) ester (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

=CH₂


RN 393520-85-9 HCAPLUS
 CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-
 (4R)-4-hydroxy-L-prolyl-3-amino-2-oxohexanoyl-, 7-(2-propenyl) ester (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 393520-87-1 HCAPLUS
 CN 1,4-Dithia-7-azaspiro[4.4]nonane-8-carboxamide, N-acetyl-L-.alpha.-
 glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[1-[oxo(2-
 propenylamino)acetyl]butyl]-, bis(1,1-dimethylethyl) ester, (8S)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-89-3 HCAPLUS

CN 1,4-Dithia-7-azaspiro[4.4]nonane-8-carboxamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]-, 2-(1,1-dimethylethyl) ester, (8S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 393520-91-7 HCAPLUS

CN 1,4-Dithia-7-azaspiro[4.4]nonane-8-carboxamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393520-93-9 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-
 (3S)-3-amino-.alpha.,2-dioxo-.beta.-propyl-1-pyrrolidinepropanoyl-,
 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—OBu-t

RN 393520-95-1 HCAPLUS


CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-
(3S)-3-amino-.alpha.,2-dioxo-.beta.-propyl-1-pyrrolidinepropanoyl-,
6-(2-propenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 393520-97-3 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-3-methyl-L-valyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-99-5 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-3-methyl-L-valyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-01-2 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-isoleucyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-03-4 HCAPLUS

CN L-Valinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-N-[(1S)-2-methyl-1-[[[(4R)-4-[[[1-[oxo(2-propenylamino)acetyl]butyl]amino]carbonyl]-3-thiazolidinyl]carbonyl]propyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-05-6 HCAPLUS

CN L-Valinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-N-[(1S)-2-methyl-1-[[[(4R)-4-[[[1-[oxo(2-propenylamino)acetyl]butyl]amino]carbonyl]-3-thiazolidinyl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-07-8 HCAPLUS

CN L-Valinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-N-[(1S)-1-[[[(4R)-1,1-dioxido-4-[[[1-[oxo(2-propenylamino)acetyl]butyl]amino]carbonyl]-3-thiazolidinyl]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-09-0 HCAPLUS
 CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-L-prolyl-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) 7-(2-propenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

=CH₂

RN 393521-11-4 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-L-prolyl-3-amino-2-oxohexanoyl-, 7-(2-propenyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-13-6 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-15-8 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393521-17-0 HCAPLUS


CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(2S,3aS,7aS)-octahydro-1H-indole-2-carbonyl-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) 7-(2-propenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 393521-19-2 HCAPLUS
 CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(2S,3aS,7aS)-octahydro-1H-indole-2-carbonyl-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 393521-21-6 HCAPLUS
 CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(2S,3aS,7aS)-octahydro-1H-indole-2-carbonyl-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 393521-23-8 HCAPLUS
 CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(2S,3aS,7aS)-octahydro-1H-indole-2-carbonyl-3-amino-2-oxohexanoyl-, 7-(2-propenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

= CH₂

RN 393521-25-0 HCAPLUS
 CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(5R)-5-phenyl-L-prolyl-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CO₂H

RN 393521-27-2 HCAPLUS
 CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(5R)-5-phenyl-L-prolyl-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OBu-t


RN 393521-29-4 HCAPLUS
 CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(5R)-5-phenyl-L-prolyl-3-amino-2-oxohexanoyl-, 7-(2-propenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CO₂H

RN 393521-31-8 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-3-methyl-L-valyl-L-valyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-33-0 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-3-methyl-L-valyl-L-valyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-35-2 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-5-methyl-L-norleucyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-37-4 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-5-methyl-L-norleucyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-39-6 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(1S)-1,2,3,4-tetrahydro-1-isoquinolinecarbonyl-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-41-0 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(1S)-1,2,3,4-tetrahydro-1-isoquinolinecarbonyl-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-43-2 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(1S)-1,2,3,4-tetrahydro-1-isoquinolinecarbonyl-3-amino-2-oxohexanoyl-, 7-(2-propenyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-45-4 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-3-cyclohexyl-L-alanyl-L-prolyl-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-47-6 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-3-cyclohexyl-L-alanyl-L-prolyl-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-49-8 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-3-cyclohexyl-L-alanyl-L-prolyl-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) 7-(2-propenyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-51-2 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S,5S)-5-amino-1,2,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl-3-amino-2-oxohexanoyl-, 6-propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393521-53-4 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(2S)-2-piperidinecarbonyl-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) 7-propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

-OBu-t




RN 393521-55-6 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(2S)-2-piperidinecarbonyl-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) 7-propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

-OBu-t

RN 393521-57-8 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(2S)-2-piperidinecarbonyl-3-amino-2-oxohexanoyl-, 7-propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-59-0 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(2S)-2-piperidinecarbonyl-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-61-4 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(2S)-2-piperidinecarbonyl-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-65-8 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(4S)-4-phenyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-, 7-propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-67-0 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(4S)-4-phenyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-69-2 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(4S)-4-phenyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393521-72-7 HCAPLUS


CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-2-cyclohexylglycyl-(8S)-1,4-dithia-7-azaspiro[4.4]nonane-8-carbonyl-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 393521-74-9 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxoheptanoyl-, 7-(2-propenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393521-77-2 HCAPLUS


CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valylglycyl-(3S)-3-amino-2-oxoheptanoyl-, 7-(2-propenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 393521-79-4 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-, 7-ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-81-8 HCAPLUS

CN Glycinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-82-9 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-(aminooxoacetyl)butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-84-1 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-(carboxycarbonyl)butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-91-0 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-94-3 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-, 7-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-98-7 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-[[[1-methylethyl]amino]oxoacetyl]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-01-5 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxo-5-hexenoyl-, 7-(2-propenyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-04-8 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxo-5-hexenoyl-, 7-ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-09-3 HCAPLUS

CN Glycinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-N-2-propynyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-12-8 HCAPLUS

CN Glycinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-14-0 HCAPLUS

CN Glycinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-N-propyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-17-3 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxo-5-hexynoyl-, 7-(2-propenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393522-20-8 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-phenylglycyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


-CO₂H

RN 393522-22-0 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-methylglycyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


CO₂H

RN 393522-24-2 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-
(2S)-2-azetidinecarbonyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

CO₂H

RN 393522-26-4 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-
(4R)-4-(carboxymethoxy)-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 393522-28-6 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-30-0 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-phenylalanyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-32-2 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-isoleucyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393522-34-4 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-2-piperidinecarbonyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CO₂H

RN 393522-36-6 HCAPLUS
 CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-
 (3S)-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-(3S)-3-amino-2-oxohexanoyl-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-39-9 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-
(4R)-4-thiazolidinecarboxyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 393522-42-4 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-S-
methyl-L-cysteinyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-44-6 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-3-(methylsulfonyl)-L-alanyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-46-8 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-S-(carboxymethyl)-L-cysteinyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-48-0 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-S,S-dioxido-L-methionyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-50-4 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-propyl-(3R)-3-amino-4-(methylthio)-2-oxobutanoyl-, 7-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-52-6 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-
(4S)-4-[[(phenoxyacetyl)amino]methyl]-L-prolyl-(3S)-3-amino-2-
oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-55-9 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-
(4S)-4-[(benzoylamino)methyl]-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 393522-59-3 HCAPLUS


CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-
(4S)-4-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]methyl]-L-prolyl-(3S)-3-
amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 393522-62-8 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-
(4S)-4-[[(3-phenoxybenzoyl)amino]methyl]-L-prolyl-(3S)-3-amino-2-
oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-65-1 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-
(4R)-4-[[(phenylsulfonyl)amino]methyl]-L-prolyl-(3S)-3-amino-2-oxohexanoyl-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-68-4 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4R)-4-[[(9H-fluoren-9-ylmethoxy) carbonyl] amino]-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-71-9 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4S)-4-[[[(phenylamino) carbonyl] amino] methyl]-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-74-2 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-
(4R)-4-(benzoylamino)-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




RN 393522-76-4 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-
(4R)-4-[(4-methoxybenzoyl)amino]-L-prolyl-(3S)-3-amino-2-oxohexanoyl-

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-79-7 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-
 (4R)-4-[(4-phenoxybenzoyl)amino]-L-prolyl-(3S)-3-amino-2-oxohexanoyl-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-81-1 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-
 (4R)-4-[(3-phenoxybenzoyl)amino]-L-prolyl-(3S)-3-amino-2-oxohexanoyl-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-84-4 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-
(4R)-4-(phenylmethyl)-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 393522-87-7 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-
(4R)-4-[(4-methoxyphenyl)methyl]-L-prolyl-(3S)-3-amino-2-oxohexanoyl-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-90-2 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-
(4R)-4-(2-propenyl)-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




RN 393522-93-5 HCAPLUS


CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-
(4R)-4-[(1,3-benzodioxol-5-ylcarbonyl)amino]-L-prolyl-(3S)-3-amino-2-
oxohexanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 393522-96-8 HCAPLUS
 CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-
 (4R)-4-[(4-fluorobenzoyl)amino]-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-99-1 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-
(4R)-4-[[(2-methylpropoxy) carbonyl] amino]-L-prolyl-(3S)-3-amino-2-
oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-02-9 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-
(4R)-4-[(phenylsulfonyl) amino]-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 393523-04-1 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-
(4R)-4-[[(4-methoxyphenyl) sulfonyl] amino]-L-prolyl-(3S)-3-amino-2-
oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-06-3 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-
(4R)-4-[[(phenylamino) carbonyl] amino]-L-prolyl-(3S)-3-amino-2-oxohexanoyl-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-09-6 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4R)-4-[[[(4-methoxyphenyl)amino]carbonyl]amino]-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-12-1 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-.alpha.-aspartyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-15-4 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-.alpha.-glutamyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-18-7 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-phenylalanyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-21-2 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-
(4R)-4-amino-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-24-5 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-
(4S)-4-(carboxymethyl)-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 393523-27-8 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-seryl-L-valyl-L-prolyl-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-29-0 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-alanyl-L-valyl-L-valyl-L-prolyl-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-31-4 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-histidyl-L-valyl-L-prolyl-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-33-6 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-asparaginyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-35-8 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-
(4S)-4-phenyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-37-0 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-
(3S)-3-methyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-39-2 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-(2-carboxyethyl)glycyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-41-6 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[2-(3,4-dimethoxyphenyl)ethyl]glycyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-43-8 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-
[(4S)-4-amino-4-carboxybutyl]glycyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 393523-45-0 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-ornithyl-L-valyl-
L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-47-2 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-D-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-49-4 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-allothreonyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-51-8 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-.beta.-phenyl-L-phenylalanyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-53-0 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-(2S)-2,4-diaminobutanoyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-55-2 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-aspartyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-57-4 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-59-6 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-threonyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-60-9 HCAPLUS

CN Glycine, N-acetyl-L-alanyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-62-1 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-leucyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-64-3 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[2-(benzoylamino)ethyl]glycyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-65-4 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[2-[(3-phenoxybenzoyl)amino]ethyl]glycyl-(3S)-3-amino-2-oxohexanoyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 393523-67-6 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[3-(benzoylamino)propyl]glycyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-69-8 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-
[(5S)-5-amino-5-carboxypentyl]glycyl-(3S)-3-amino-2-oxohexanoyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 393523-71-2 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-3-(1-naphthalenyl)-
L-alanyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 393523-73-4 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-3-(2-naphthalenyl)-L-alanyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-75-6 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-homoseryl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-77-8 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-.alpha.-methyl-L-phenylalanyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-79-0 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-leucyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-81-4 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-3-methyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-84-7 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-seryl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-86-9 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-threonyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-89-2 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-norleucyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-92-7 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-.beta.-phenyl-L-phenylalanyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-94-9 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-O-methyl-L-seryl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-95-0 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-asparaginyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-97-2 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-glutaminyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-99-4 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-phenylalanyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-00-0 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-methionyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-02-2 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-cysteinyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-07-7 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-[oxo(2-propenylamino)acetyl]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-09-9 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-isoleucyl-N-[(1S)-1-[oxo(2-propenylamino)acetyl]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-12-4 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-5-methyl-2-oxohexanoyl-, 7-(2-propenyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 394203-31-7 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-2-cyclohexylglycyl-3-cyclohexylalanyl-3-amino-2-oxohexanoyl-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B



RN 394203-32-8 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-2-cyclohexylglycyl-3-cyclohexylalanyl-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394203-33-9 HCAPLUS

CN Glycinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-2-cyclohexylglycyl-(8S)-1,4-dithia-7-azaspiro[4.4]nonane-8-carbonyl-3-amino-2-oxohexanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394203-34-0 HCAPLUS


CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-2-cyclohexylglycyl-3-(methylsulfonyl)alanyl-3-amino-2-oxohexanoyl- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




IT 91-00-9, Diphenylmethanamine 98-79-3, L-Pyroglutamic acid 106-95-6, Allyl bromide, reactions 109-80-8, 1,3-Propanedithiol 618-27-9 870-46-2, tert-Butyl carbazate 2746-25-0, p-Methoxybenzyl bromide 2999-46-4, Ethyl isocyanoacetate 5437-45-6, Benzyl bromoacetate 7188-38-7, tert-Butyl isocyanide 13726-69-7 53308-95-5 64187-48-0 71989-28-1 138021-87-1 166196-06-1 216378-84-6
 RL: RCT (Reactant); RACT (Reactant or reagent) (prepn. of novel peptides as NS3-serine protease inhibitors of hepatitis C virus)
 RN 91-00-9 HCAPLUS
 CN Benzenemethanamine, .alpha.-phenyl- (9CI) (CA INDEX NAME)




RN 98-79-3 HCAPLUS
 CN L-Proline, 5-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 106-95-6 HCAPLUS
 CN 1-Propene, 3-bromo- (9CI) (CA INDEX NAME)




RN 109-80-8 HCAPLUS
 CN 1,3-Propanedithiol (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)




RN 618-27-9 HCAPLUS
 CN L-Proline, 4-hydroxy-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).




RN 870-46-2 HCAPLUS
 CN Hydrazinecarboxylic acid, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 2746-25-0 HCAPLUS
 CN Benzene, 1-(bromomethyl)-4-methoxy- (9CI) (CA INDEX NAME)




RN 2999-46-4 HCAPLUS
 CN Acetic acid, isocyano-, ethyl ester (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 5437-45-6 HCAPLUS
 CN Acetic acid, bromo-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 7188-38-7 HCAPLUS
 CN Propane, 2-isocyano-2-methyl- (9CI) (CA INDEX NAME)



RN 13726-69-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-hydroxy-, 1-(1,1-dimethylethyl) ester,
(2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 53308-95-5 HCAPLUS

CN L-Norvaline, N-[(1,1-dimethylethoxy)carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 64187-48-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-hydroxy-, 2-methyl 1-(phenylmethyl)
ester, (2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 71989-28-1 HCAPLUS


CN L-Methionine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 138021-87-1 HCAPLUS
 CN L-Cysteine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-S-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 166196-06-1 HCAPLUS
 CN Hexanoic acid, 3-[[[1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 216378-84-6 HCAPLUS
 CN L-Cysteine, N-[(1,1-dimethylethoxy)carbonyl]-S-methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 16217-15-5P 35418-16-7P 58948-98-4P
 63307-62-0P 76203-43-5P 91229-91-3P
 113490-83-8P 116611-55-3P 127949-74-0P
 132622-88-9P 132622-90-3P 132622-91-4P
 132622-94-7P 143935-63-1P 150908-38-6P
 153074-95-4P 160801-74-1P 160806-17-7P
 163437-14-7P 176486-63-8P 185304-19-2P
 189215-88-1P 189215-89-2P 189215-90-5P
 224645-82-3P 224645-88-9P 237421-53-3P
 244132-29-4P 273221-98-0P 276888-16-5P
 276888-17-6P 276888-55-2P 276888-56-3P
 393513-18-3P 393524-17-9P 393524-22-6P
 393524-24-8P 393524-25-9P 393524-27-1P
 393524-29-3P 393524-31-7P 393524-36-2P
 393524-38-4P 393524-40-8P 393524-42-0P
 393524-47-5P 393524-49-7P 393524-52-2P
 393524-55-5P 393524-57-7P 393524-63-5P
 393524-67-9P 393524-68-0P 393524-70-4P
 393524-72-6P 393524-75-9P 393524-83-9P
 393524-95-3P 393525-00-3P 393525-03-6P
 393525-07-0P 393525-09-2P 393525-11-6P
 393525-16-1P 393525-18-3P 393525-21-8P
 393525-23-0P 393525-25-2P 393525-27-4P
 393525-29-6P 393525-31-0P 393525-36-5P
 393525-37-6P 393525-38-7P 393525-39-8P
 393525-40-1P 393525-41-2P 393525-42-3P
 393525-43-4P 393525-44-5P 393525-45-6P
 394203-35-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (prepn. of novel peptides as NS3-serine protease inhibitors of
 hepatitis C virus)

RN 16217-15-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-oxo-, 2-methyl 1-(phenylmethyl) ester,
 (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 35418-16-7 HCAPLUS


CN L-Proline, 5-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 58948-98-4 HCAPLUS


CN Acetic acid, isocyano-, potassium salt (9CI) (CA INDEX NAME)



● K


RN 63307-62-0 HCAPLUS

CN 1H-Benzotriazole, 1-hydroxy-, ammonium salt (9CI) (CA INDEX NAME)

● NH₃

RN 76203-43-5 HCAPLUS


CN Acetic acid, isocyano-, 2-propenyl ester (9CI) (CA INDEX NAME)



RN 91229-91-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 5-oxo-, bis(1,1-dimethylethyl) ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 113490-83-8 HCAPLUS

CN 6,10-Dithia-2-azaspiro[4.5]decane-2,3-dicarboxylic acid, 3-methyl 2-(phenylmethyl) ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 116611-55-3 HCAPLUS

CN Carbamic acid, [(1S)-1-(hydroxymethyl)butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 127949-74-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 5-oxo-4-(phenylmethyl)-, bis(1,1-dimethylethyl) ester, (2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 132622-88-9 HCAPLUS

CN L-Proline, 4-hydroxy-, phenylmethyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 132622-90-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-hydroxy-, 1-(1,1-dimethylethyl) 2-(phenylmethyl) ester, (2S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 132622-91-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-[(methylsulfonyl)oxy]-, 1-(1,1-dimethylethyl) 2-(phenylmethyl) ester, (2S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 132622-94-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-cyano-, 1-(1,1-dimethylethyl) 2-(phenylmethyl) ester, (2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 143935-63-1 HCAPLUS


CN L-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-3-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 150908-38-6 HCAPLUS


CN Hydrazinecarboxylic acid, 2-[[[(diphenylmethyl)amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 153074-95-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-(phenylmethyl)-, 1-(1,1-dimethylethyl) ester, (2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 160801-74-1 HCAPLUS

CN Carbamic acid, [(1S)-1-formylbutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 160806-17-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 5-oxo-4-[2-oxo-2-(phenylmethoxy)ethyl]-, bis(1,1-dimethylethyl) ester, (2S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163437-14-7 HCAPLUS

CN Butanoic acid, 2-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-(methylsulfonyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 176486-63-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-, 1-(1,1-dimethylethyl) ester, (2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 185304-19-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-azido-, 1-(1,1-dimethylethyl)
2-(phenylmethyl) ester, (2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189215-88-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-[(methylsulfonyl)oxy]-, 2-methyl
1-(phenylmethyl) ester, (2S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189215-89-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-azido-, 2-methyl 1-(phenylmethyl)
ester, (2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189215-90-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-methyl 1-(phenylmethyl) ester, (2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 224645-82-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-(2-propenyl)-, 1-(1,1-dimethylethyl) ester, (2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 224645-88-9 HCAPLUS


CN 1,2-Pyrrolidinedicarboxylic acid, 4-[2-oxo-2-(phenylmethoxy)ethyl]-, 1-(1,1-dimethylethyl) ester, (2S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 237421-53-3 HCAPLUS
 CN 1,2-Pyrrolidinedicarboxylic acid, 5-oxo-4-(2-propenyl)-, bis(1,1-dimethylethyl) ester, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 244132-29-4 HCAPLUS
 CN L-Alanine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-3-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273221-98-0 HCAPLUS
 CN 1,2-Pyrrolidinedicarboxylic acid, 4-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]methyl]-, 1-(1,1-dimethylethyl) ester, (2S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 276888-16-5 HCAPLUS

CN L-Norvaline, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-, methyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 276888-17-6 HCAPLUS

CN Carbamic acid, [(1S)-1-(hydroxymethyl)butyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 276888-55-2 HCAPLUS

CN Carbamic acid, [(1S)-1-formylbutyl]-, 9H-fluoren-9-ylmethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 276888-56-3 HCAPLUS

CN Glycine, N-[(3S)-3-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-2-hydroxy-1-oxohexyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393513-18-3 HCAPLUS

CN L-Proline, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-17-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-(phenylmethyl) ester, (2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-22-6 HCAPLUS

CN L-Glutamic acid, N-acetyl-L-.alpha.-glutamyl-, 1,25-bis(1,1-dimethylethyl) 21-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-24-8 HCAPLUS

CN L-Glutamic acid, N-acetyl-L-.alpha.-glutamyl-, 1,25-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-25-9 HCAPLUS

CN L-Valine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-, 1,2-bis(1,1-dimethylethyl) 3-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-27-1 HCAPLUS

CN L-Valine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 393524-29-3 HCAPLUS

CN L-Valine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-,
1,2-bis(1,1-dimethylethyl) 4-(phenylmethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-31-7 HCAPLUS

CN L-Valine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-,
1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-36-2 HCAPLUS


CN 6,10-Dithia-2-azaspiro[4.5]decane-2,3-dicarboxylic acid,
2-(1,1-dimethylethyl) 3-methyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393524-38-4 HCAPLUS
CN 6,10-Dithia-2-azaspiro[4.5]decane-2,3-dicarboxylic acid,
2-(1,1-dimethylethyl) ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393524-40-8 HCAPLUS
CN 6,10-Dithia-2-azaspiro[4.5]decane-3-carboxylic acid, methyl ester,
hydrochloride, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 393524-42-0 HCAPLUS
CN 6,10-Dithia-2-azaspiro[4.5]decane-3-carboxylic acid, 2-[cyclohexyl[(1,1-
dimethylethoxy)carbonyl]amino]acetyl-, methyl ester, (3S)- (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 393524-47-5 HCAPLUS

CN 6,10-Dithia-2-azaspiro[4.5]decane-3-carboxylic acid, 2-[cyclohexyl[(1,1-dimethylethoxy)carbonyl]amino]acetyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-49-7 HCAPLUS

CN 6,10-Dithia-2-azaspiro[4.5]decane-3-carboxylic acid, 2-(aminocyclohexylacetyl)-, methyl ester, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 393524-52-2 HCAPLUS

CN Glycine, N-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-1-oxohexyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)




RN 393524-55-5 HCAPLUS


CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-2-cyclohexylglycyl-(8S)-1,4-dithia-7-azaspiro[4.4]nonane-8-carbonyl-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) 7-(2-propenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 393524-57-7 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-2-cyclohexylglycyl-(8S)-1,4-dithia-7-azaspiro[4.4]nonane-8-carbonyl-3-amino-

2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-63-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-[(4-methoxyphenyl)methyl]-5-oxo-, bis(1,1-dimethylethyl) ester, (2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-67-9 HCAPLUS

CN L-Proline, 4-(phenylmethyl)-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-68-0 HCAPLUS

CN L-Proline, 4-[(4-methoxyphenyl)methyl]-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-70-4 HCAPLUS

CN L-Proline, 4-(2-propenyl)-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-72-6 HCAPLUS

CN 3-Pyrrolidineacetic acid, 5-carboxy-, .alpha.-(phenylmethyl) ester, (3S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-75-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-[(4-methoxyphenyl)methyl]-, 1-(1,1-dimethylethyl) ester, (2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-83-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-chloro-, 1-(1,1-dimethylethyl) 2-(phenylmethyl) ester, (2S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393524-95-3 HCAPLUS
 CN L-Proline, 4-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]methyl]-, (4R)-,
 mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 393524-94-2
 CMF C21 H22 N2 O4

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 393525-00-3 HCAPLUS
 CN Carbamic acid, [(1S)-1-[2-[(1,1-dimethylethyl)amino]-1-hydroxy-2-oxoethyl]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393525-03-6 HCAPLUS

CN Hexanoic acid, 3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-, ethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393525-07-0 HCAPLUS

CN Hydrazinecarboxamide, N-(diphenylmethyl)-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 150908-39-7


CMF C14 H15 N3 O



CM 2

CRN 104-15-4

CMF C7 H8 O3 S




RN 393525-09-2 HCAPLUS

CN Hexanoic acid, 3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-


[[[(diphenylmethyl)amino]carbonyl]hydrazono]-, ethyl ester, (3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 393525-11-6 HCAPLUS
CN Hexanoic acid, 3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-
[[[(diphenylmethyl)amino]carbonyl]hydrazono]-, (2Z,3S)- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 393525-16-1 HCAPLUS
CN Glycine, N-[(3S)-3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-1-
oxohexyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393525-18-3 HCAPLUS
CN Glycine, N-[(3S)-3-amino-2-hydroxy-1-oxohexyl]-, ethyl ester,
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 393525-21-8 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(2S,3S)-3-amino-2-hydroxyhexanoyl-, 1,2-bis(1,1-dimethylethyl) 7-ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393525-23-0 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(2R,3S)-3-amino-2-hydroxyhexanoyl-, 1,2-bis(1,1-dimethylethyl) 7-ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393525-25-2 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(2S,3S)-3-amino-2-hydroxyhexanoyl-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393525-27-4 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(2R,3S)-3-amino-2-hydroxyhexanoyl-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393525-29-6 HCAPLUS

CN Glycinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(2S,3S)-3-amino-2-hydroxyhexanoyl-N-2-propenyl-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393525-31-0 HCAPLUS

CN Glycinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(2R,3S)-3-amino-2-hydroxyhexanoyl-N-2-propenyl-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

$$= \text{CH}_2$$

RN	393525-36-5	HCAPLUS
CN	Glycine, N-[(3S)-3-amino-2-hydroxy-1-oxohexyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)	


Absolute stereochemistry.



RN 393525-37-6 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-hydroxyhexanoyl-, 1,2-bis(1,1-dimethylethyl) 7-(2-propenyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393525-38-7 HCAPLUS

CN Hexanamide, 3-amino-2-hydroxy-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 393525-39-8 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-(2-amino-1-hydroxy-2-oxoethyl)butyl]-,

bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393525-40-1 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-(aminooxoacetyl)butyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393525-41-2 HCAPLUS

CN Hexanoic acid, 3-amino-2-hydroxy-, ethyl ester, hydrochloride, (3S)- (9CI) (CA INDEX NAME)

CCOC(=O)[C@H](O)[C@@H](N)SPr

RN	393525-42-3	HCAPLUS
CN	L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-(2-ethoxy-1-hydroxy-2-oxoethyl)butyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)	


Absolute stereochemistry.



RN 393525-44-5 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-(carboxyhydroxymethyl)butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393525-45-6 HCAPLUS

CN Hexanoic acid, 3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-[[[(diphenylmethyl)amino]carbonyl]hydrazono]-, (2E,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 394203-35-1 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-2-cyclohexylglycyl-(8S)-1,4-dithia-7-azaspiro[4.4]nonane-8-carbonyl-3-amino-2-hydroxyhexanoyl-, 1,2-bis(1,1-dimethylethyl) 7-(2-propenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

